Summary von Willebrand disease (VWD) is a common autosomally inherited bleeding disorder associated with mucosal or trauma-related bleeding in affected individuals. VWD results from either a quantitative or qualitative de®ciency of von Willebrand factor (VWF) ± a glycoprotein with essential roles in primary haemostasis and as a carrier of coagulation factor VIII (FVIII) in the circulation. In recent years the identi®cation of mutations in the VWF gene in patients with VWD has improved our understanding of the structure and function of the VWF protein, and has illustrated the importance of speci®c regions of VWF for its interaction with other components of the vasculature. The underlying genetic lesions and associated molecular pathology have been identi®ed in many cases of type 2A, type 2B, type 2M, type 2N and type 3 VWD. However in the most common variant, type 1 VWD, the causative molecular defect is unknown in the large majority of cases. In the absence of an understanding of the molecular pathology underlying type 1 VWD, precise diagnosis and classi®cation of this common disorder remains problematic.
Introduction

Historical perspective
von Willebrand factor (VWF) has merited extensive study since its characterization during the 1980s. This can be attributed both to its pivotal role in blood coagulation mechanisms, and to its association with the most common inherited bleeding disorder in man, von Willebrand disease (VWD). The development of an understanding of the pathophysiology of VWF and VWD originates from the description in 1926 of a family from Fo Èglo È, an island in the A Ê land archipelago of Finland. von Willebrand, (1926) reported a family with a serious hereditary bleeding disorder which he described as à pseudohaemophilia' ± so-called because, unlike the sexlinked recessive inheritance seen in haemophilia A and B, it was inherited as an autosomal dominant trait. von Willebrand attributed the disorder to a platelet or vessel wall defect. Further reports describing the symptoms noted by von Willebrand were made but it was not until the 1950s, when techniques for measuring factor VIII (FVIII) levels in blood were developed, that the nature of VWD (and haemophilia A) began to be understood. The autosomal inheritance pattern for VWD, contrasting with the sex-linkage of classic haemophilia A, indicated that VWF was distinct from FVIII. Despite this evidence, the decreased FVIII activity seen in patients with VWD caused confusion about the respective roles of FVIII and VWF in the circulation and the separate nature of haemophilia A and VWD. It was not until the 1970s that the nature of the relationship in the circulation between FVIII and VWF began to be understood.
During the 1980s the isolation of the FVIII and VWF proteins and the advent of modern molecular techniques led to the cloning of the genes for FVIII (Gitschier et al., 1984; Toole et al., 1984) and VWF (Ginsburg et al., 1985; Lynch et al., 1985; Sadler et al., 1985; Verweij et al., 1985) . The peptide sequence of VWF was also determined (Titani et al., 1986) . Molecular cloning of the VWF gene allied with VWF protein studies has now allowed scrutiny of the structure and function of VWF and its interaction with FVIII. Functional sites of the VWF gene have been localized and the role of VWF in primary haemostasis has been de®ned. The study of this functionality has shown that VWD may result from an array of VWF defects causing distinct clinical manifestations of the disease, not all of which are understood at the molecular level.
VWF function
VWF is an adhesive plasma glycoprotein synthesized in endothelial cells (Jaffe et al., 1974; Sussman & Rand, 1982) and megakaryocytes (Nachman et al., 1977; Sporn et al., 1985) . Although synthesized as a protomer, the function of the VWF protein is dependent on its assembly into a pool of disulphide bonded, structurally heterogeneous high molecular weight multimers (Hoyer & Shainoff, 1980) . VWF has a central role in primary haemostasis where it mediates platelet adhesion to damaged vascular subendothelium and subsequent platelet aggregation. This is achieved via binding of VWF to speci®c receptors on the platelet surface glycoproteins Ib and IIb/IIIa complex, as well as to ligands on the subendothelium (Colombatti & Bonaldo, 1991; Wise et al., 1991; Fressinaud et al., 1994) . The adhesive function of VWF is particularly important under conditions of high shear in the vasculature, i.e. in small blood vessels (Alevriado et al., 1993; Savage et al.,1996) , where platelet adhesion and hence normal primary haemostasis is absolutely dependent on VWF. VWF also acts as a stabiliser of FVIII in the circulation. This is achieved by the formation of a noncovalently bound VWF-FVIII complex that protects FVIII from degradation by activated protein C, and localizes FVIII to sites of platelet plug and subsequent clot formation (Weiss et al., 1977; Koedam et al., 1988; Koedam et al., 1990; Wise et al., 1991; Vlot et al., 1995; Koppelman et al., 1996) . Reduced levels of VWF are consequently associated with reduced levels of circulating FVIII (Nishino et al., 1989; Mazurier, 1992) , explaining the low FVIII levels seen in patients with VWD and the earlier confusion regarding the distinction between FVIII and VWF.
VWF ± gene and synthesis
The VWF gene, located on the short arm of chromosome 12 (Ginsburg et al., 1985; Verweij et al., 1985) , resides within 178 kb of genomic DNA. It consists of 52 exons, the largest, exon 28, spanning 1.4 kb (Mancuso et al., 1989) . The VWF gene is transcribed into a 9-kb mRNA which is translated to produce a 2813 amino acid product (Verweij et al., 1986) , designated pre-pro-von Willebrand factor (Bonthron et al., 1987) . This precursor polypeptide consists of a 22 amino acid signal peptide, a 741 amino acid propeptide and a 2050 residue mature subunit ( Figure 1a ). The mature VWF sequence is comprised of a series of homologous sequence domains thought to have arisen as a result of gene segment duplications ( Figure 1a ) (Bonthron et al., 1987; Verweij et al., 1986; SheltonInloes et al., 1987a) . Functional sites of the VWF molecule have been localized to areas of these repeat units, as illustrated ( Figure 1b ) in relation to the domain structure.
A partial, highly homologous VWF pseudogene, encompassing exons 23±34 of the functional gene, resides on chromosome 22 (Patracchini et al., 1989) . Ninety-seven percent sequence homology with the authentic VWF gene on chromosome 12 suggests a recent evolutionary origin of the pseudogene . The homologous nature of the pseudogene may complicate analyses of the VWF gene when examining genomic DNA. Gene conversion involving the VWF pseudogenic sequence has been proposed as a mechanism for introducing mutations into the VWF gene sequence. Four such candidate events have been described (Holmberg et al., 1993; Zhang et al., 1993; Eikenboom et al., 1994; Eikenboom et al., 1998) , all of which are located between the posterior of exon 27 and the anterior of exon 28. The clustering of these candidate gene conversion events is suggestive of a common mechanism, possibly mediated by recombination across the large, and highly homologous, exon 28 region of the VWF gene and the corresponding pseudogene sequence.
VWF multimers range in size from 0.5 to 20 Megadaltons (Ruggeri & Zimmerman, 1981) , the largest multimers The molecular biology of von Willebrand disease being the most biologically active (Martin et al., 1981; Girma et al., 1987) . Prior to multimerization the VWF primary translation product undergoes a complex series of post-translational modi®cations including prosequence cleavage, dimerization and glycosylation. After cleavage of the signal peptide the monomeric propolypeptide forms dimers within the endoplasmic reticulum (ER) (Wagner & Marder, 1984; Roarke et al., 1989) . Dimerization requires initial glycosylation of the VWF propolypeptide (Wagner et al., 1986) . Dimerization is mediated by disulphide bridge formation between cysteine residues within the carboxy terminal domains (Fowler et al., 1985; Wagner et al., 1987; Voorberg et al., 1991) . Multimerization of dimers is a transGolgi event, where assembly proceeds by noncovalent interaction between pro-VWF dimers (Wagner et al., 1986) . These interactions are then stabilized by interchain pairing of disulphides within the amino terminus of the mature VWF subunit (Wagner & Marder, 1984; Wagner et al., 1987; Voorberg et al., 1990) . The 741 amino acid propolypeptide sequence, known to be important for correct multimer formation Verweij et al., 1988; Wise et al., 1988) and targeting of the endothelial cell storage Weibel-Palade body (Wagner et al., 1991) , is cleaved during this process. However, cleavage of the propolypeptide is not an absolute requirement for multimer formation. The 741 residue propolypeptide is identical in sequence to von Willebrand antigen II (VWAgII) (Fay et al., 1986; Montgomery & Zimmerman, 1978) .
von Willebrand disease (VWD)
VWD is a congenital bleeding disorder resulting from quantitative or qualitative defects of the VWF protein. It is considered to be the most common inherited bleeding disorder in humans with an estimated prevalence ranging from 3±4 per 100 000 to as high as 1.3% of the population (Holmberg & Nilsson, 1985; Rodeghiero et al., 1987; Bloom, 1991; Werner et al., 1993) . Accurate estimation of prevalence is complicated by variable penetrance of the disease phenotype, it is most pronounced in type 1 VWD which comprises 70% of all cases (Miller et al., 1979; Holmberg & Nilsson, 1985) . Selection pressures which may be associated with the high frequency of VWD in humans are not readily apparent. It has been suggested that VWD may offer protection against heart disease, as has been demonstrated in a porcine model (Fass et al., 1979) , however, there is no evidence for such a protective effect in humans (Gunby, 1980) . The late onset of heart disease may not be expected to affect reproductive ®tness signi®cantly.
VWD is a heterogenous disorder. More than 20 variants/subtypes have been described (Table 1) (Ruggeri & Zimmerman, 1987; Sadler, 1994) . The current classi®cation of VWD merged a number of previously distinct subtypes, reducing the number of subgroups to 6 (Sadler, 1994) . The three primary VWD types were retained (type 1, type 2 and type 3 VWD), preserving the quantitative/qualitative distinction originally described by Holmberg & Nilsson (1975) . Type 1 VWD refers to a partial quantitative de®ciency of VWF and is considered typically to be autosomal dominant in inheritance, although de®nitive diagnosis is complicated by reduced penetrance and variable expressivity. It is characterized by parallel reductions in VWF antigen (VWF:Ag), VWF activity and FVIII levels, resulting in a mild to moderate bleeding diathesis. The distribution pattern of VWF multimers is normal. Type 3 VWD is a clinically severe quantitative disorder resulting from markedly reduced or absent platelet and plasma VWF (less than 5 units per decilitre (U/dl), normal range 50±150 U/dl). FVIII activity is also markedly reduced (ranges from <1±10 U/dl) due to lack of stabilization by VWF. The mode of inheritance in type 3 VWD is autosomal recessive or, in some cases, a manifestation of homozygous (or compound heterozygous) type 1 VWD. Estimates of the prevalence of type 3 VWD range from 0.5 to 5.3 per million, depending on the population studied (Mannucci et al., 1984; Berliner et al., 1986) . Type 2 VWD includes a series of subtypes (2A, 2B, 2M, and 2N VWD) characterized by a qualitative defect in VWF function. Type 2 variants are thought to make up 20±30% of all VWD diagnoses (Holmberg & Nilsson, 1985) . Inheritance is autosomal dominant, with the exception of type 2N VWD and a rare type 2A variant ± type IIC VWD. Type 2A VWD is associated with the absence of the largest VWF multimers and disproportionately low levels of VWF ristocetin cofactor activity (VWF:Ricof) relative to VWF:Ag. Patients with type 2B VWD usually, but not always, exhibit reduced high molecular weight multimers. This condition is characterized in the laboratory by enhanced ristocetin-induced platelet agglutination (RIPA), although VWF:Ricof may be normal. Type 2M VWD is associated with speci®c defects in platelet/VWF interaction and the presence of the normal range of multimers, although there may be some banding pattern anomalies. Type 2N VWD is a recessive disorder resulting from defective VWF binding to FVIII and consequently low levels of circulating FVIII.
Molecular classi®cation of VWD and variable expressivity of VWD phenotype
VWF is subject to a complex processing pathway and has many functional interactions. It is therefore likely that defects at a number of genetic loci may be implicated in a VWD phenotype. However, with the exception of defects associated with platelet-type pseudo-VWD or acquired VWD all mutations identi®ed in VWD patients to date are associated with the VWF locus (Table 2 and Figure 2 ). The VWF gene is polymorphic in nature and, as many polymorphisms occur close to VWD-associated mutations, this needs to be considered when analysing VWD candidate mutations.
Bleeding symptoms can vary widely between patients with VWD, even between affected members of the same family (Miller et al., 1979; Abildgaard et al., 1980; Blomba Èck et al., 1992) . The disease phenotype is confounded by a series of modifying factors known to affect VWF antigen levels. These include ABO blood group, Lewis blood group, oestrogens (including oral contraceptive pill and hormone replacement therapy use), age, thyroid hormone, exercise and stress (Rickles et al., 1976; Gill et al., 1987; Mazurier et al., 1988; Orstavik et al., 1989; Bloom, 1991; Triplett, 1991) . The effects of ABO blood group on VWF:Ag levels have been well documented. Mean VWF:Ag levels in healthy blood type O individuals are approximately 75 U/dl compared to 123 U/dl in group A and B individuals (Gill et al., 1987) . The mechanisms underlying the observation that some type 1 VWD patients with similar VWF levels may have very different bleeding tendencies, even within the same family (Abildgaard et al., 1980) , remain obscure. Some of these differences may be accounted for by the factors referred to above, be the result of multiple heterozygosity for mutations or polymorphisms in the VWF gene (Eikenboom et al., 1993a) or promoter (Keightley et al., 1999; Harvey et al., 2000) , or re¯ect the impact of modi®er loci outwith the VWF gene.
Genetic family studies in VWD
It is a prerequisite of a clinical diagnostic service that full genetic counselling is available to patients and families with VWD. Counselling should be undertaken as a matter of course, and before any genetic studies are carried out. This will ensure that the individuals concerned have an appreciation of the inheritance of VWD in their family and will understand, with regard to providing informed consent, exactly what information may be obtained by any proposed investigations. Further counselling should be carried out to explain the results of genetic tests when they become available. Genetic counselling must always be nondirective and should be undertaken by individuals who have signi®cant experience in the clinical management of VWD, together with a good understanding of the molecular basis of the disorder. The requirement for molecular genetic family studies in VWD is limited. When required, precise molecular diagnosis may be achieved in the qualitative VWD variants (types 2A, 2B, 2M, 2N) by screening for common mutations. However, the causative mutation is unknown in the majority of cases of VWD, and gene linkage analysis using restriction fragment length polymorphisms (RFLPs) or variable number of tandem repeat (VNTR) sequences in the VWF gene may be useful.
The cloning of VWF cDNA led to the identi®cation of many RFLPs that have been used in genetic studies in VWD. The informativity of VWF gene RFLPs is, however, limited by their biallalic nature, and the interpretation of RFLP data in autosomally inherited VWD is more complex than in X-chromosome linked hereditary disorders. In order to determine the RFLP haplotype associated with VWD it may be necessary to carry out multiple restriction fragment analyses. The presence of the VWF pseudogene on chromosome 22 is a further complicating factor and polymerase chain reaction (PCR) primers must be designed to take this into account. Intron 40 of the VWF gene contains several very informative VNTR sequences, and these are useful for PCR-based gene linkage studies in VWD Ploos van Amstel & Reitsma, 1990; Cumming et al., 1992) . The investigator should be aware of the potential for instability in the number of VNTR repeat sequences between generations (Eikenboom et al., 1993b; Haddad & Sparrow, 1997) .
Overall, gene linkage analysis has limited applications in family studies in VWD, its main use being for prenatal (Bahnak et al., 1988; Bernardi et al., 1988; Bignell et al., 1990; Caekebeke-Peerlinck et al., 1990; Peake et al., 1990; Standen et al., 1990) , although Nichols & Ginsburg (1997) pointed out that these linkage studies did not attain statistical signi®cance for each individual family studied. Casana et al. (1999) reported a candidate mutation (T393M) in 7 affected individuals from the same family. Abuzenadah et al. (1999) reported three propeptide nonsense mutations (S49R, R324Q and R273W) associated with type 1 VWD in Turkish patients, the R273W mutation existing in the homozygous state in the two families in whom it was identi®ed.
Dominant-negative effects and type 1 VWD
It has been postulated that some mutations in the heterozygous state which result in an abnormal VWF protein may have an additional secondary effect, leading to a greater reduction in VWF levels than may be expected from a simple loss of function from one allele. Such defects cause symptomatic type 1 VWD in heterozygotes. A classical type 1 VWD phenotype may therefore result from the presence of a`dominant negative mutation' (Herskowitz, 1987) . This class of defect gives rise to a mutant gene product which, in heterozygotes, inhibits the function of the wild-type gene product. A dominantnegative effect has been demonstrated in a class of dominant type 2A VWD. This qualitative defect in VWF was a consequence of the production of mutant VWF subunits which failed to multimerize in the Golgi . Eikenboom et al. (1996) reported two mutations associated with type 1 VWD in two separate families, 3389G > T and 3445T > C, resulting in amino acid substitutions C1149R and C1130F, respectively. Both mutations disrupted disulphide bond mediated cysteine pairing in the D3 domain of VWF. Furthermore, the reduced quantity of VWF multimers secreted had a normal size distribution. The 3445T > C transition was shown by coexpression of recombinant mutant and normal VWF to result in a dose dependent decrease in the secretion of VWF. This observation was consistent with a`dominantnegative' effect. The authors suggested that the mutated subunits may be retained in the endoplasmic reticulum.
Co-expression studies of recombinant C1149 normal and R1149 mutant VWF appeared to con®rm the retention of defective VWF dimers in the endoplasmic reticulum (Bodo Â et al., 1998) . The C1130F mutation has been described in ®ve Italian families, likely to be subject to a founder effect, where it demonstrates clear autosomal dominant inheritance in the presence of a normal VWF multimer pattern . Other mutations which affect cysteine residues mediating disulphide bond formation in the VWF protein have been described, however, these mutations have been associated with recessive type 3 VWD alleles (Zhang et al., 1994; Eikenboom et al., 1998) . Heterozygosity for the common type 3 VWD exon 18 frameshift mutation, which results in a VWF protein containing 30 missense amino acids, does not appear to exert a dominant-negative effect on normal VWF subunits expressed from the wild-type allele (Mohlke et al., 1996) . Keeney et al. (1999) investigated the dominant-negative hypothesis by studying 12 unrelated type 1 VWD patients who had been shown to express both VWF alleles, as indicated by the presence of polymorphisms detectable at the mRNA level. The 12 patients were screened for mutations in the VWF gene multimerization domains. This revealed no DNA sequence anomalies to account for the observed disease phenotype.
The available evidence suggests that defects affecting VWF multimerization are not a common cause of dominant type 1 VWD.
Recessive inheritance in type 1 VWD
In some cases, type 1 VWD may appear to be due to heterozygosity for a type 3 VWD mutation. Peake et al. (1990) studied a family showing apparently coexisting dominant and recessive inheritance associated with a deletion of exon 42 of the VWF gene. A severely affected (type 3 VWD) member of the family was homozygous for the deletion. Another member of the family was heterozygous for the deletion and had a type 1 VWD The molecular biology of von Willebrand disease phenotype. However, 6 other heterozygous members of the family were asymptomatic, and it was proposed that the individual with type 1 VWD was a compound heterozygote for a second undetected VWF defect. Eikenboom et al. (1993a) investigated 6 type 1 VWD patients from four families. They reported that the symptomatic type 1 probands were all compound heterozygotes, the true heterozygotes being asymptomatic or having only mild symptoms. In a study of 8 Italian type 3 and recessive type 1 VWD families, Eikenboom et al. (1998) reported ®ve families with a milder phenotype (0.5±3.5 U/dl VWF : Ag) than that associated with classic type 3 VWD. Three other families had probands classi®ed as type 1 VWD (4±12 U/dl VWF : Ag) showing recessive inheritance. Mutation analysis of these patients found that the`mild' type 3 VWD patients carried a combination of a null allele and a candidate missense mutation (one proband had two candidate missense mutations), suggesting that a residual level of expression of the mutant VWF allele was occurring. The three probands classi®ed as recessive type 1 VWD included one compound heterozygote and two patients where only one defective VWF was identi®ed. Large gene deletions associated with type 3 VWD were not detected in a panel of 19 type 1 VWD patients (SheltonInloes et al., 1987b). Eikenboom et al. (1992) were unable to detect two mutations, 2535 C > T and 2546 A > T, which occur with a high frequency in Dutch type 3 VWD patients in 17 type 1 patients . Considered together, the above studies indicate that a proportion of symptomatic type 1 VWD is associated with compound heterozygosity for a recessive type 3 VWD null allele and another defect on the expressed allele. Compound heterozygosity for VWF defects, resulting in a variable quantitative de®ciency of VWF, complicates the classi®cation of VWD when this is based on phenotypic data alone. Consistent with the autosomal recessive pattern associated with type 3 VWD, heterozygous carriers of VWF gene deletions or defects resulting in loss of VWF expression are generally asymptomatic and have normal laboratory parameters.
Type 1 VWD and type 2N VWD
In some type 1 VWD patients, unexpectedly low FVIII levels relative to VWF:Ag and VWF:Ricof have been observed. In several cases this has been shown to be due to coinheritance of type 1 (sometimes a recessive null allele) and type 2N VWD alleles (Cacheris et al., 1991; Peerlinck et al., 1992; Eikenboom et al., 1993a; Lavergne et al., 1993; Schneppenheim et al., 1994; Siguret et al., 1994; Kroner et al., 1996; Nesbitt et al., 1996; Casonato et al., 1998) . It has been suggested that compound heterozygosity for a type 2N VWD mutation may account for some of the variable expressivity seen in type 1 VWD (Eikenboom et al., 1993a) . A number of symptomatic type 1 VWD patients have also been shown to be heterozygous for R854Q (Arg91Gln) (Cacheris et al., 1991; Peerlinck et al., 1992; Eikenboom et al., 1993a) , the commonest type 2N VWD mutation which may have a frequency as high as 1% in some populations (Eikenboom et al., 1993a) .
Non-linkage of type 1 VWD to the VWF gene
It is likely that a substantial proportion of the type 1 VWD phenotype arises from a genetic defect not associated with the VWF gene. The reported 1% prevalence for type 1 VWD (Rodeghiero et al., 1987) corresponds to an allele frequency of approximately 0.005, which translates into a homozygote frequency (those expected to have type 3 VWD) of one in 40 thousand (Nichols & Ginsburg, 1997) . This is markedly greater than the observed frequency of approximately one in one million for type 3 VWD. This discrepancy could be explained by an overestimation of the prevalence of type 1 VWD or by a signi®cant loss of type 3 homozygotes. Alternatively, defects at other genetic loci could result in a type 1 VWD phenotype. Castaman et al., 1999) reported that inheritance of type 1 VWD may not cosegregate with genetic markers at the the VWF gene locus. They further investigated 11 individuals previously diagnosed with type 1 VWD as part of an epidemiological study among school children in northern Italy (Rodeghiero et al., 1987) . Haplotype analysis of the 11 index cases and their families showed clear cosegregation of the type 1 VWD phenotype with a particular VWF allele in one family and probable association in two other families. Three further index cases and their families showed a possible association but this could not be con®rmed due to limited numbers of family members studied. The ®ve remaining propositi and their families showed no association of the type 1 VWD phenotype with a particular allele.
An important factor to be considered is the capacity modi®er loci may have to affect plasma VWF levels. ABO blood group effects in humans are an example of this (Gill et al., 1987) , the mechanism involved appearing to operate at the post-translational stage. VWF is a highly glycosylated protein (Sodetz et al., 1978; Samor et al., 1982) and blood group determinants have been identi®ed on its surface (Sodetz et al., 1979) . It is thought that blood group determinants on the VWF moiety adversely affect the half-life of the VWF protein in the circulation. VWF levels in blood group O individuals are substantially lower than in individuals of other ABO blood groups, and proportionately more group O individuals have been diagnosed to have VWD (Gill et al., 1987) . It may be postulated that the mild type 1 VWD phenotype seen in some patients is related to a blood group effect and is not associated with a VWF gene defect.
An entirely dominant type 1 VWD phenotype caused by post-translational modi®cation of the VWF protein has been demonstrated in a type 1 VWD mouse model (Nichols et al., 1994; Ginsburg, 1999; Mohlke et al., 1999) . VWF synthesized in endothelial cells of the RIIIS/J mouse undergoes a novel post-translational step mediated by a modi®er gene, Galgt2. This alters the glycosylation pattern of VWF resulting in signi®cantly increased proteolysis of the protein. The net result is a marked reduction in plasma levels of VWF. Although it is unlikely that such a lineage-speci®c switch of gene expression will have also happened in humans, glycosylation effects other than those related to ABO blood group may be a possibility in a proportion of human type 1 VWD. There are over 1000 galactosyl transferases described, some of which may have the capacity to interact with VWF if inappropriately expressed in endothelial cells. However, some studies suggest that modi®-cations affecting glycosylation patterns of VWF would result in selective loss of high molecular weight multimers (Sodetz et al., 1978; Gralnick, 1983) , inconsistent with the type 1 VWD phenotype. Conversely, Federici et al. (1984) have demonstrated that carbohydrate may protect VWF against the effects of proteases but that it does not play a direct role in maintaining VWF multimeric structure. Some glycosylation defects may therefore be associated with a reduced VWF half-life but a normal VWF multimer pattern, and thus produce a VWD type 1 phenotype, as demonstrated in the mouse model above.
Promoter region polymorphisms are possible modulators of VWF gene expression and could contribute to the quantitative reduction of VWF seen in type 1 VWD. A study of 261 group O blood donors (Keightley et al., 1999) identi®ed two VWF gene promoter region polymorphic haplotypes which were associated with VWF:Ag levels. Homozygosity for haplotype 1 (±1234C/±1185A/± 1051G) was associated with a higher mean VWF:Ag level. Homozygosity for haplotype 2 (±1234T/±1185G/± 1051A) was associated with a lower mean VWF:Ag level. Heterozygotes had an intermediate level. A polymorphism at position ±1793 upstream has also been implicated in VWF levels (Harvey et al., 2000) . These ®ndings demonstrate that sequences at the VWF locus may affect (directly or indirectly) plasma VWF:Ag levels.
Type 3 VWD
Type 3 VWD is characterized by markedly reduced or absent VWF:Ag and VWF:Ricof, and resultant low levels of FVIII. Platelet VWF stores are also absent.
Inheritance of type 3 VWD
The mode of inheritance in type 3 VWD is autosomal recessive, and in some cases is a manifestation of homozygous or compound heterozygous recessive effects of mutations that may cause type 1 VWD in the heterozygous state (Weiss & Sussman, 1986; Randi et al., 1993; Castaman et al., 1995; Eikenboom et al., 1998) . The parents of affected individuals are generally asymptomatic and have normal phenotypic laboratory data (Ruggeri & Zimmerman, 1987; Nichols et al., 1991; Eikenboom et al., 1992) . Type 3 VWD has also been reported in families where other family members present with a type 1 VWD phenotype (Bloom & Peake, 1979; Wahlberg et al., 1983; Bahnak et al., 1991; Zhang et al., 1992b; Schneppenheim et al., 1994; Zhang et al., 1995; Eikenboom et al., 1998) . In these cases a combination of apparent dominant and recessive inheritance may be observed within the same family. The observation, that in some families type 3 VWD appears to represent the homozygous form of type 1 VWD while in others it is a true autosomal recessive disorder, probably re¯ects the variable penetrance of type 1 VWD (see section on type 1 VWD).
Mutations in type 3 VWD
It was originally assumed that type 3 variants of VWD would be associated with large VWF gene deletions, however, available evidence suggests this is not a frequent mechanism. The earliest studies of molecular defects associated with type 3 VWD used Southern Blot analysis to probe for large-scale gene deletions. In a group of 19 type 3 VWD patients, homozygous gene deletions were detected in only two unrelated individuals (Shelton-Inloes et al., 1987b) . In 6 patients with type 3 VWD, Ngo et al. (1988) identi®ed one individual who was homozygous for a complete VWF gene deletion and a second individual who was heterozygous for large partial deletion of the VWF gene. This second patient had an asymptomatic parent with the same abnormality, suggesting that the The molecular biology of von Willebrand disease patient had inherited a second undetected defect on the other VWF allele. Six partial gene deletions have been reported Mancuso et al., 1994; Schneppenheim et al., 1994) . More recently, a study of ®ve type 3 VWD families from the Veneto region of Italy revealed one complete VWF gene deletion .
As large gene deletions appear not to be associated with the majority of cases of type 3 VWD, it is likely that most mutations are small insertions, deletions or single nucleotide substitutions. Due to the large size of the VWF gene, methods to reduce the amount of DNA sequence to be examined for the presence of mutations have been employed to investigate this. One generalized approach is to target CGA codons within a gene coding sequence. Thesè mutational hot-spots' are prone to deamination of the ®rst base, with the resultant conversion of the codon to a TGÀ stop' (Cooper & Krawczak, 1990) . This strategy has been applied to the 11 CGA codons within the VWF gene and nonsense mutations have been identi®ed at ®ve of these (Bahnak et al., 1991; Eikenboom et al., 1992; Zhang et al., 1992a; Eikenboom et al., 1993a; Schneppenheim et al., 1994; Eikenboom et al., 1998) . However, the success of this approach may be limited to populations where there is genetic homogeneity of type 3 VWD alleles. Screening of 10 alleles representing ®ve Italian type 3 families revealed only one CGA to TGA nonsense mutation .
Type 3 VWD associated alleles, silent at the mRNA level, have been identi®ed by comparative analysis of VWF genomic DNA and platelet VWF mRNA. This technique relies on the detection of heterozygous coding sequence polymorphisms within the genomic DNA sequence and comparing them to cDNA synthesized from platelet VWF mRNA. Heterozygotes at the genomic DNA level will appear to be hemizygous at the cDNA level in the presence of a silent allele (`loss of heterozygosity' [LOH]) . This approach, although it does not identify the speci®c mutation, has identi®ed nondeletion defects resulting in complete loss of VWF mRNA expression in several patients with type 3 VWD . It should be noted that a similar observation by Nichols et al. (1991) was a misinterpretation due to the presence of a previously unknown VWF gene polymorphism in the primer sequence which abolished ampli®cation of one allele .
A range of nonsense and frameshift mutations, predicted to result in loss of VWF protein expression, or expression of a truncated protein, have been identi®ed in type 3 VWD families (Bahnak et al., 1991; Eikenboom et al., 1992 (Schneppenheim et al., 1994; Zhang et al., 1994; Zhang et al., 1995; Eikenboom et al., 1998) . Three intron/exon boundary splice site mutations, resulting in exon skipping or aberrant splicing, have also been described (Zhang et al., 1994; Mertes et al., 1994; Eikenboom et al., 1998) .
The most common mutation described in several populations of type 3 VWD patients is a single cytosine deletion at position 2680 in a 6 cytosine stretchspanning nucleotides (nt) 2680±2686 of the VWF gene (Zhang et al., 1992b) . This mutation results in a frameshift within exon 18 and creates a VWF protein containing 30 missense amino acids within the mature subunit. In a study of 24 Swedish type 3 VWD patients (48 VWF alleles), 50% were shown to carry this mutation (Zhang et al., 1992c) . The exon 18 single base deletion has also been demonstrated in the German (Schneppenheim et al., 1994) and Dutch populations, and has been shown to be the mutation responsible for VWD in the family originally reported by von Willebrand (von Willebrand, 1926; Zhang et al., 1993) . However, this mutation has not been identi®ed in ®ve Italian type 3 VWD families . A study of 37 type 3 VWD patients of multiethnic origin detected mutations, mainly resulting in null alleles, throughout the VWF gene sequence with no particularly prevalent mutation being detected (Baronciani et al., 2000) .
Molecular biology of qualitative von Willebrand disease
Type 2 VWD variants are, by de®nition, the result of qualitative de®ciencies of VWF. Inheritance is dominant, with the exception of type 2N VWD and a rare variant of type 2A VWD, previously called type IIC VWD. The bleeding tendency in type 2 variants is generally more pronounced than in type 1 VWD. It has been estimated that type 2 VWD comprises 20±30% of all VWD diagnoses (Hoyer et al., 1983; Holmberg & Nilsson, 1985) . According to current de®nitions (Sadler, 1994) Nichols & Ginsburg, 1997) . The majority of mutations associated with type 2A VWD result in single amino acid substitutions. The number of point mutations or candidate mutations identi®ed in patients with a type 2A VWD phenotype continues to increase (VWF Database ± http://mmg2.im.med.umich.edu/VWF). Most of these point mutations lie within the posterior part of exon 28 in a 168 amino acid segment from 1505 to 1672 of`prepro' VWF, representing the A2 domain of the VWF protein (Figures 1 and 2 ). Molecular modelling of the A2 domain indicates that these mutations are likely to affect VWF protein folding to some extent (Jenkins et al., 1998) . Several amino acid substitutions, C1272R (Cys509Arg) (Lavergne et al., 1992) and V1314F (Val551Phe) and other mutations, now con®rmed by expression studies, have been identi®ed in the anterior region of exon 28 within the A1 domain in individual cases of type 2A VWD Ribba et al., 1999) . In addition, a duplication event encompassing S1352-A1386 (Ser589-Ala623 of the mature subunit) and an in-frame deletion of exons 26±34 have also been reported to result in a type 2A VWD phenotype (Bernardi et al., 1990; Bernardi et al., 1993; Gaucher et al., 1995a; Meyer et al., 1997) . The most common mutation, R1597W (Arg834Trp) in the A2 domain, may account for up to a third of type 2A VWD Bowen et al., 1990; Sugiura et al., 1991; Inbal et al., 1992; Meyer et al., 1997) .
In a large study of type 2 VWD patients in France, Meyer et al. (1997) investigated 45 unrelated cases exhibiting a type 2A VWD phenotype. Thirty-two of the patients had mutations in the A2 domain between amino acids 1505±1672 (742±909 of the mature subunit), including three new candidate mutations. They reported a high frequency for the R1597W (Arg834Trp) and an I1628T (Ile865Thr) substitution, which together accounted for one-third of cases. In addition, four new mutations were described within the A1 domain. These new mutations, C1272G (Cys509Gly) (con®rmed by expression studies), R1308H (Arg545His), R1315C (Arg552Cys) and C1458Y (Cys695Tyr) (candidate mutations), are located within areas previously linked to platelet GpIb binding (Matsushita & Sadler, 1995) (Figures 1 and 2 ). These regions have previously been shown to carry mutations associated with a type 2B VWD phenotype. Interestingly, the R1308H candidate mutation associated with a type 2A VWD phenotype contrasts with a R1308C (Arg545Cys) mutation found in type 2B VWD patients which was shown to result in increased af®nity for platelet GpIb (Inbal et al., 1993) . A further patient was shown to carry the R1308H mutation and exhibit a type 2A VWD rather than 2B VWD phenotype. A similar ®nding has been reported in a patient with a type 2B VWD associated genotype, V1316M (Val553Met) and a type 2A VWD phenotype (Gaucher et al., 1995b) . Ribba et al. (2001) have recently described 10 patients (6 families) who exhibit a type 2A VWD phenotype associated with a R1315C change, in an area of the A1 loop associated with type 2B VWD mutations.
Group 1 and group 2 mutations in type 2A VWD
Site-directed mutagenesis of recombinant VWF and subsequent expression studies have revealed two distinct molecular mechanisms resulting in the characteristic type 2A VWD loss of large and intermediate molecular weight multimers. Causative mutations are designated group 1 and group 2 . Group 1 mutations are associated with impaired assembly and secretion of normal VWF multimers. Retention of mutant VWF in the endoplasmic reticulum results in decreased high and intermediate molecular weight VWF multimers in both plasma and platelets. It is assumed that the larger multimers carrying this group of mutation contain a high number of mutant subunits which interfere with normal VWF processing and secretion, resulting in retention within the cell. Smaller multimers are less likely to be affected and are secreted normally. This mechanism is consistent with a dominant negative effect.
Group 2 VWF gene mutations in type 2A VWD are associated with normal processing and secretion of VWF multimers. Loss of large and intermediate molecular weight multimers then occurs in plasma due to increased susceptibility to proteolysis at the site in the A2 domain between T1605 (Thr842) and M1605 (Met843) by a speci®c plasma metalloprotease (Furlan et al., 1996; Tsai, 1996) . The clari®cation of these two distinct (group 1 and group 2) mechanisms may explain the observation of intact platelet VWF multimers in some type 2A patients and not in others (Weiss et al., 1983; Gralnick et al., 1985a) .
Type 2A VWD and current classi®cation of VWD A number of rare type 2 VWD variants have now been reclassi®ed as type 2A (Table 1) . These include types IIC, IID, IIE, IIF, IIG, and type IIH (Ruggeri et al., 1982; Kinoshita et al., 1984; Mannucci et al., 1986 , 1987; Ruggeri & Zimmerman, 1987) . These subtypes were distinguished by their multimeric patterns on agarose gels. The common feature of these variants is the loss of the highest molecular weight VWF multimers, subdivision being based on the pattern of¯anking bands around the remaining multimers. Not all of these variants have been characterized at the molecular level. The variant formerly known as type IIC VWD (Ruggeri et al., 1982) is usually inherited as an autosomal recessive trait and is characterized by loss of large VWF multimers and an increase in the quantity of VWF dimer. Platelet multimers can be normal (Batle et al., 1986) . Mutations responsible for the type IIC variant have been identi®ed in exons 11±17, corresponding to the D2 domain of the VWF propeptide (Figure 1 ). These consist of one deletion, three insertions and four missense mutations (Mannucci et al., 1986; Schneppenheim et al., 1995; Gaucher et al., 1998; Holmberg et al., 1998) .
The variant formerly known as type IID VWD, characterized by the absence of high molecular weight multimers and decreased proteolysis (Kinoshita et al., 1984) , has been linked to a point mutation, resulting in a C2010R (Cys1247Arg) substitution, in two unrelated patients. Expression studies indicate that this mutation is responsible for defective disulphide bonding of C-terminal domains, thus impairing dimer formation and subsequent multimerization (Gaucher et al., 1995c; Gaucher & Mazurier, 1996; Schneppenheim et al., 1996a) . Further mutations ®tting this category have also been described (Schneppenheim et al., 2001; Enayat et al., 2001) . Type IIE VWD also results in impaired dimerization of VWF subunits and has been associated with a single base deletion (Schneppenheim et al., 1996a) . Type IIF VWD is characterized by an absence of high molecular weight multimers with normal platelet VWF (Mannucci et al., 1986) . Type IIG VWD shows loss of high and intermediate multimers and increased susceptibility to proteolysis of platelet VWF (Gralnick et al., 1987) . Type IIH is characterized by the loss of the largest VWF multimers. It should be noted that the subtle distinctions made at the VWF level between these type 2A VWD subtypes are generally not re¯ected in the clinical manifestation of the condition.
Type Ib VWD (Hoyer et al., 1983) and type I`platelet discordant' VWD (Mannucci et al., 1985) , both associated with decreased platelet-dependent function and reduction of large VWF multimers, have also been reclassi®ed as type 2A VWD (Sadler, 1994) . A candidate mutation R1374H (Arg611His) has been described in two unrelated families with a platelet discordant VWD phenotype (Castaman et al., 1995) . This candidate mutation falls within the A1 domain of VWF, normally associated with type 2B VWD mutations, and is listed currently in the VWF online database (http://mmg2.im.med.umich.edu/VWF) as belonging to unclassi®ed VWD.
Type 2B VWD
Type 2B VWD is associated with increased af®nity of VWF for platelet GpIb. High molecular weight VWF multimers are usually variably absent from plasma but normal in the platelet pool (Ruggeri & Zimmerman, 1980) . Platelet aggregation in the presence of ristocetin (RIPA) is enhanced. The VWF:Ag and FVIII activity may range from low to normal. Mild thrombocytopenia is common in type 2B VWD and can be exacerbated during physical exercise, stress, and/or pregnancy (Giles et al., 1987; Rick et al., 1987) . Type 2B VWD is usually inherited as an autosomal dominant trait, and accounts for less than 20% of all type 2 VWD.
Mutations in type 2B VWD
Type 2B VWD is associated with point mutations in the anterior region of exon 28, corresponding to the A1 domain of VWF containing the GpIb binding domain (Figures 1 and 2) (Mohri et al., 1988; Mohri et al., 1989; Vicente et al., 1990; Sugimoto et al., 1991) . These result in an increased af®nity of the VWF A1 domain for platelet GpIb. Over 20 such dominant mutations have been described (VWF Database ± http://mmg2.im. med.umich.edu/VWF). Almost all of these mutations have been shown by mutant recombinant VWF expression studies to be associated with increased af®nity for platelet surface GpIb (Ichinose et al., 1991; Cooney et al., 1992; Kroner et al., 1992; Ribba et al., 1992) . As previously described, two type 2B VWDassociated mutations, V1316M and R1308C, have also been detected in two patients with a type 2A VWD phenotype (Gaucher et al., 1995b; Meyer et al., 1997) . Four common type 2B VWD mutations, R1306W, R1308C, V1316M and R1341Q (Arg543Trp, Arg545Cys, Val553-Met, and Arg578Gln) (Cooney et al., 1991; Lillicrap et al., 1991; Randi et al., 1991; Murray et al., 1992) are clustered within a 35 amino acid stretch of the A1 domain and account for approximately 80% of type 2B VWD patients reported . The large majority of type 2B VWD cases are therefore readily detectable by genotypic analysis. Molecular modelling of eight type 2B VWD mutations, including the four common ones, suggest that many 2B mutations act by perturbing the heparin binding site of VWF. This interference to the local VWF protein structure is likely to modulate an allosteric signal to the GpIb binding site, resulting in a conformational change to the A1 domain which enhances its af®nity for platelet GpIb (Jenkins et al., 1998) .
Some rare VWD variants previously classi®ed as type I have been reclassi®ed as type 2B VWD (Table 1) . These variants exhibit a normal VWF multimer pattern but show enhanced RIPA, a diagnostic requirement for type 2B VWD. They include type I New York, type I Malmo È, and type I Sydney (Holmberg et al., 1986; Wise et al., 1988; Wylie et al., 1988) . Type I New York and type I Malmo È represent the same amino acid substitution P1266L (Pro503Leu). This missense mutation is located within the cluster of mutations observed for classic type 2B VWD and results in similar increased binding to platelet GpIb (Holmberg et al., 1993) . An I1309V (Ile546Val) substitution has been reported in association with an unusual type 2B phenotype with markedly increased platelet-dependent function and partial preservation of high molecular weight VWF multimers (Federici et al., 1997) .
Type 2B VWD may be confused with platelet-type pseudo VWD (Weiss et al., 1982) which is very similar in presentation. Platelet-type pseudo VWD is associated with mutations in the platelet GpIb receptor resulting in increased af®nity for VWF (Miller et al., 1991; Russell & Roth, 1991; Miller, 1996) . Platelet-type pseudo VWD and type 2B VWD are distinguishable by plasma and platelet mixing experiments between control and patient samples.
Type 2M VWD
Type 2M VWD variants are characterized by decreased platelet-dependent function in the presence of normal VWF multimer distribution, although multimer banding patterns on high resolution gels may be atypical (Sadler, 1994) . Most of the VWD type 2M variants were previously classi®ed as type I VWD (Table 1) , and in many cases are unlikely to be distinguished from type I due to current diagnostic limitations. They include variants with normal multimers but decreased VWF ristocetin cofactor activity, such as type 2M Milwaukee (Mancuso et al., 1996) and a variant with larger than normal plasma multimers, VWD Vicenza (Mannucci et al., 1988; Zieger et al., 1997) . Also included are variants which, on high-resolution agarose gels, show subtle differences from normal multimer structure (types IC and ID), and variants which have uncleaved pro-VWF attached to the multimers (Howard et al., 1982; Ciavarella et al., 1985; Montgomery et al., 1986; Mannucci et al., 1988; Lopez-Fernandez et al., 1991; Rabinowitz et al., 1991) .
Mutations in type 2M VWD
Mutations associated with type 2M VWD have been identi®ed within the disulphide loop of the VWF A1 domain (amino acids C1272 ± C1458 (Cys509 ± Cys695), the region associated with platelet GPIb binding (Figures 1  and 2 ). Many putative mutations have now been con®rmed by expression studies of recombinant mutant VWF. The variant known as type 2M VWD Milwaukee is associated with a deletion of R1392 ± Q1402 (Arg629-Gln639 of the mature subunit) resulting in a failure of VWF to bind to platelet GpIb (Mancuso et al., 1996) . The variant previously referred to as VWD type B (normal multimer assembly with undetectable ristocetin cofactor activity despite normal platelet binding to botrocetin) was shown to be due to a G1324S (Gly561Ser) substitution, again within the A1 domain . Meyer et al. (1997) detected an alternative amino acid substitution at this residue, G1324A (Gly561Ala), which exhibits a similar phenotype. Interestingly, amino acid 1324 lies within the main cluster of type 2B VWD mutations (amino acids 1303±1341). The candidate missense mutations, F1369I (Phe606Ile) (Gaucher et al., 1995a) and I1425P (Ile662Phe) (Hillery et al., 1998) , have been con®rmed in two separate families with a type 2M phenotype. Furthermore, molecular modelling of the three dimensional structure of the VWF A1 domain predicts that these mutations are not in the same cluster as the majority of type 2B VWD mutations (Hillery et al., 1998; Jenkins et al., 1998) . Candidate type 2M VWD mutations include a deletion of K1408 (Lys645) (Hilbert et al., 2000) . Meyer et al. (1997) have identi®ed four further candidate mutations within the A1 loop that are likely to be associated with a 2M phenotype. A R1315C (Arg552Cys) candidate 2M mutation has been described in a Spanish 2M family (Casana et al., 1998) . Type 2M Vicenza has been associated with three candidate mutations, R1205H (Arg442His), Y1146C (Tyr383Cys) and R2379C (Arg1616Cys) in a study of Italian and German families (Schneppenheim et al., 2000) . Lavergne et al., (1999) have described ®ve candidate type 2M VWD mutations (V1279I), (Val516Ile), L1282R (Leu519Arg), S1285F (Ser522Phe), L1296P (Leu533Pro) and D1302G (Asp539Gly), many now con®rmed by expression studies. A further candidate mutation, A1361T (Ala598Thr), has been identi®ed in a single female type 2M VWD patient (Al-Homsi et al., 1999) . A recent study has identi®ed ®ve mutations involving cysteine residues in the D3 domain of VWF which result in an apparent type 2M VWD phenotype . The number of 2M mutations, or candidate mutations, described continues to increase.
Misclassi®cation of type 2M VWD
Limitations in the diagnostic testing repertoire available for routine diagnosis of VWD may lead to misclassi®cation of type 2M VWD. The VWF:Ag level measured in type 1 VWD patients is usually similar to the ristocetin cofactor activity. Nitu-Whalley et al. (2000) studied 317 patients originally diagnosed as type 1 VWD. A subgroup of 30 patients (17 unrelated familes) were identi®ed who had a discrepant VWF:RiCof/VWF:Ag ratio (< 0.7) in the presence of normal multimers and decreased RIPA. DNA sequencing of the A1 domain was performed in all 30 patients. Mutations were identi®ed in 9 families, including four previously described VWD type 2M mutations. Four candidate 2M mutations were also described (V1279F (Val516Phe), I1416T (Ile653Thr), R1399C (Arg636Cys) and Y1321D (Tyr558Asp)). No mutations were found in the A1 domain of the remaining 8 families, although this did not necessarily exclude a diagnosis of type 2M VWD. These ®ndings suggested that a proportion of patients previously diagnosed to have type 1 VWD may actually have type 2M VWD. In summary, patients with a con®rmed reduced ratio of VWF:RiCof/VWF:Ag in the presence of normal VWF multimer distribution should be further investigated for type 2M VWD.
Type 2N VWD
Originally termed VWD Normandy after the province in France in which the ®rst patient to be described was born (Mazurier, 1992) , type 2N VWD is an autosomal recessive disorder characterized by a marked decrease in the af®nity of VWF for FVIII (Nishino et al., 1989; Mazurier et al., 1990a) . Affected individuals exhibit normal VWF multimers, VWF:Ag and VWF:Ricof (normal platelet-dependent function; primary haemostasis is normal), but have a substantially reduced VWF binding capacity for FVIII. Low levels of plasma FVIII (generally ³ 5 U/dl) are found in individuals who are homozygous or compound heterozygous for VWD type 2N mutations, re¯ecting the rapid proteolysis of FVIII in the circulation. Conventional coagulation screening tests may be misleading, leading to misdiagnosis as mild or moderate haemophilia A (Nishino et al., 1989; Mazurier et al., 1990b; Mazurier, 1992) , and studies of the binding capacity of VWF for FVIII are required for a de®nitive diagnosis of type 2N VWD. Misdiagnosis has implications for the genetic counselling and treatment of bleeding episodes in this group of patients. Although type 2N VWD is less common than haemophilia A, the former diagnosis should be considered in individuals with mild or moderate FVIII de®ciency if inheritance is not clearly X-linked.
Mutations in type 2N VWD
To date, 14 mutations associated with type 2N VWD have been described within the N-terminus of VWF in a region previously shown to contain the FVIII binding domain (Figures 1 and 2) (Foster et al., 1987; Takahashi et al., 1987; Bahou et al., 1989; Wise et al., 1991) . These include R782W (Arg19Trp) and H817Q (His54Gln) (Kroner et al., 1991) , G785E (Gly22Glu) (Gu et al., 1997) , E787K (Glu24Lys) (Schneppenheim et al., 1996b) , T791M (Thr28Met) (Gaucher et al., 1991b; Tuley et al., 1991) , Y795C (Tyr32Cys) (Hilbert et al., 1999a; Schneppenheim et al., 1999) , M800V (Met37Val) (Hilbert et al., 1999a) , R816W (Arg53Trp) (Gaucher et al., 1991a) , R854Q (Arg91Gln) (Cacheris et al., 1991; Gaucher et al., 1991b; Kroner et al., 1991) , R854W (Arg91Trp) (Bowen et al., 1998) , C858F (Cys95Phe) Jorieux et al., 1998) and C788R (Cys25Arg) (Allen et al., 2000) . Pseudo-homozygotes for type 2N VWD have been identi®ed, with a single mutant allele and a silent allele (Cacheris et al., 1991; Peerlinck et al., 1992; Eikenboom et al., 1993a; Lavergne et al., 1993; Nesbitt et al., 1996; Schneppenheim et al., 1996b) . Some type 2N VWD pseudo-homozygotes have been misdiagnosed previously as type 1 VWD.
The R854Q mutation is the most common type 2N VWD mutation, accounting for more than half of all reported 2N families. Between them the R854Q, R816W and T791M substitutions account for more than threequarters of all reported VWD type 2N cases. Expression of recombinant VWF containing many of these mutations has con®rmed their role in defective FVIII binding (Cacheris et al., 1991; Kroner et al., 1991; Tuley et al., 1991; Jorieux et al., 1992; Wise et al., 1993; Kroner et al., 1996; Meyer et al., 1997) . These studies have shown that VWF carrying the R854Q mutation retains some residual ability to bind FVIII (Lavergne et al., 1993) whilst the G785E, T791M and R816W mutations completely abolish binding. The milder phenotype reported in a patient who was compound heterozygous for the R782W and H817Q mutations suggested that these mutations are also less severe in their effect . The C858F mutation has been identi®ed in a compound heterozygote (R854Q) and again is associated with a moderate FVIII de®ciency . Patients with`milder' type 2N VWD mutations which maintain residual FVIII binding have higher FVIII levels in the circulation, in the region of 30±40 U/dl (Lavergne et al., 1993; Meyer et al., 1997) .
Several VWF gene mutations associated with defective FVIII binding also result in aberrant VWF multimer patterns, C788Y (Cys25Tyr), D879N (Asp116Asn), C1060R (Cys297Arg) Jorieux et al., 1998) , Q290H (Gln290His) (Hilbert et al., 1999b ), C788R and C1225G (Allen et al., 2000 . Con®rmation of the role of the Cys297Arg mutation by expression studies illustrates that regions of VWF other than the FVIII binding domain can result in a type 2N VWD phenotype. However, describing mutations lying outside the VWF/FVIII binding domain as type 2N VWD mutations may not always be advisable. It is likely that many such mutations lead to major structural changes in the VWF molecule and that loss of the ability to bind FVIII effectively is a secondary consequence.
Molecular analysis of VWD qualitative (type 2) variants has provided insight into the structure and function of the VWF protein. Whilst the majority of severe quantitative (type 3) VWD can be explained by mutations in and around the VWF locus the same cannot be said for milder quantitative (type 1) VWD. It is likely that insights gained from the human genome mapping project, perhaps in the ®eld of single nucleotide polymorphism (SNP) analysis, will in the near future shed light on the underlying molecular pathology of this enigmatic disorder. 
